Form 4: Zevra Therapeutics CEO Neil McFarlane Sells Shares Under 10b5-1 Plan

Neil F. McFarlane, CEO of Zevra Therapeutics, sold shares of common stock on February 13th and 14th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Neil F. McFarlane, the President and CEO of Zevra Therapeutics, Inc., reported the sale of ZVRA common stock.
• The transactions occurred on February 13, 2025, and February 14, 2025.
• On February 13, 2025, 61,273 shares were sold at a price of $7.8571 per share.
• On February 14, 2025, 30,544 shares were sold at a price of $8.0527 per share.
• Following these transactions, McFarlane directly owns 191,516 shares of Zevra Therapeutics common stock.
• The sales were executed under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was adopted on October 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged 10b5-1 trading plan. It doesn't necessarily indicate a negative outlook, but it's a notable transaction.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of insider trading. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• Shareholders may react to the news of the CEO selling shares, although the pre-planned nature of the sales may mitigate concerns.

Key Dates

Keywords

Form 4, ZEVRA THERAPEUTICS, ZVRA, Neil F. McFarlane, Stock Sale, 10b5-1 Plan, Insider Trading